|
[1]
|
Pietras, R.J. and Weinberg, O.K. (2005) Antiangiogenic steroids in human cancer therapy. Evidence-Based Complementary and Alternative Medicine, 2, 49-57.
doi:10.1093/ecam/neh066
|
|
[2]
|
Tascilar, M., et al. (2006) Complementary and alternative medicine during cancer treatment: Beyond innocence. The Oncologist, 11, 732-741.
doi:10.1634/theoncologist.11-7-732
|
|
[3]
|
Hagerty, R.G., et al. (2005) Communicating with realism and hope: Incurable cancer patients’ views on the disclosure of prognosis. Journal of Clinical Oncology, 23, 1278-1288.
|
|
[4]
|
Surh, Y.J. and Chun, K.S. (2007) Cancer chemopreventive effects of curcumin. Advances in Experimental Medicine and Biology, 595, 149-172.
doi:10.1007/978-0-387-46401-5_5
|
|
[5]
|
Chainani-Wu, N. (2003) Safety and anti-inflammatory activity of curcumin: A component of tumeric (Curcuma longa). The Journal of Alternative and Complementary Medicine, 9, 161-168. doi:10.1089/107555303321223035
|
|
[6]
|
Duvoix, A., et al. (2005) Chemopreventive and therapeutic effects of curcumin. Cancer Letters, 223, 181-190.
doi:10.1016/j.canlet.2004.09.041
|
|
[7]
|
Hsu, C.H. and Cheng, A.L. (2007) Clinical studies with curcumin. Advances in Experimental Medicine and Biology, 595, 471-480. doi:10.1007/978-0-387-46401-5_21
|
|
[8]
|
Bisht, M., Bist, S.S. and Dhasmana, D.C. (2010) Biological response modifiers: Current use and future prospects in cancer therapy. Indian Journal of Cancer, 47, 443-451. doi:10.4103/0019-509X.73559
|
|
[9]
|
Johnson, J.J. and Mukhtar, H. (2007) Curcumin for chemoprevention of colon cancer. Cancer Letters, 255, 170181. doi:10.1016/j.canlet.2007.03.005
|
|
[10]
|
Ferguson, L.R. and Philpott, M. (2007) Cancer prevention by dietary bioactive components that target the immune response. Current Cancer Drug Targets, 7, 459-464.
|
|
[11]
|
Singh, S. and Khar, A. (2006) Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anti-Cancer Agents in Medicinal Chemistry, 6, 259-270.
|
|
[12]
|
Jagetia, G.C. and Aggarwal, B.B. (2007) “Spicing up” of the immune system by curcumin. Journal of Clinical Immunology, 27, 19-35. doi:10.1007/s10875-006-9066-7
|
|
[13]
|
Sharma, R.A., Gescher, A.J. and Steward, W.P. (2005) Curcumin: The story so far. European Journal of Cancer, 41, 1955-1968. doi:10.1016/j.ejca.2005.05.009
|
|
[14]
|
John, V.D., Kuttan, G. and Krishnankutty, K. (2002) Antitumour studies of metal chelates of synthetic curcumanoids. Journal of Experimental & Clinical Cancer Research, 21, 219-224.
|
|
[15]
|
Hadi, S.M., et al. (2000) Putative mechanism for anticancer and apoptosis-inducing properties of plant-derived polyphenolic compounds. IUBMB Life, 50, 167-171.
|
|
[16]
|
Yoshino, M., et al. (2004) Prooxidant activity of curcumin: Copper-dependent formation of 8-hydroxy-2’-deoxyguanosine in DNA and induction of apoptotic cell death. Toxicology in Vitro, 18, 783-789.
doi:10.1016/j.tiv.2004.03.009
|
|
[17]
|
Thompson, K.H., et al. (2004) Complementary inhibition of synoviocyte, smooth muscle cell or mouse lymphoma cell proliferation by a vanadyl curcumin complex compared to curcumin alone. Journal of Inorganic Biochemistry, 98, 2063-2070.
doi:10.1016/j.jinorgbio.2004.09.011
|
|
[18]
|
Garcea, G., et al. (2005) Consumption of the putative chemopreventive agent curcumin by cancer patients: Assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiology Biomarkers & Prevention, 14,120-125.
|
|
[19]
|
Adams, B.K., et al. (2004) Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorganic & Medicinal Chemistry, 12, 3871-3883. doi:10.1016/j.bmc.2004.05.006
|
|
[20]
|
Sun, C.Y., et al. (2004) Experimental study on anticancer effect of curcumin on Raji cells in Vitro. Zhongguo Zhong Xi Yi Jie He Za Zhi, 24, 1003-1006.
|
|
[21]
|
Shao, Z.M., et al. (2002) Curcumin exerts multiple suppressive effects on human breast carcinoma cells. International Journal of Cancer, 98, 234-240.
doi:10.1002/ijc.10183
|
|
[22]
|
Kim, J.H., et al. (2002) Microarray-based analysis of anti-angiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: Crucial involvement of the down-regulation of matrix metalloproteinase. Cancer Science, 93, 1378-1385.
doi:10.1111/j.1349-7006.2002.tb01247.x
|
|
[23]
|
Bemis, D.L., Katz, A.E. and Buttyan, R. (2006) Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opinion on Investigational Drugs, 15, 1191-1200. doi:10.1517/13543784.15.10.1191
|
|
[24]
|
Campbell, F.C. and Collett, G.P. (2005) Chemopreventive properties of curcumin. Future Oncology, 1, 405-414.
doi:10.1517/14796694.1.3.405
|
|
[25]
|
Shanmugam, M.K., Kannaiyan, R. and Sethi, G. (2011) Targeting cell signaling and apoptotic pathways by dietary agents: Role in the prevention and treatment of cancer. Nutrition and Cancer, 63, 161-173.
doi:10.1080/01635581.2011.523502
|
|
[26]
|
Su, S.J., et al., The novel targets for anti-angiogenesis of genistein on human cancer cells. Biochemical Pharmacology, 69, 307-318. doi:10.1016/j.bcp.2004.09.025
|
|
[27]
|
Ravindranath, M.H., et al. (2004) Anticancer therapeutic potential of soy isoflavone, genistein. Advances in Experimental Medicine and Biology, 546, 121-165.
|
|
[28]
|
Kyle, E., et al. (1997) Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Molecular Pharmacology, 51, 193-200.
|
|
[29]
|
Lazarevic, B., et al. (2012) The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy.The British Journal of Nutrition, 108, 1-10.
|
|
[30]
|
Lazarevic, B., et al. (2011) Efficacy and safety of shortterm genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: A randomized, placebo-controlled, double-blind phase 2 clinical trial. Nutrition and Cancer, 63, 889-898.
doi:10.1080/01635581.2011.582221
|
|
[31]
|
Sasamura, H., et al. (2004) Antiproliferative and antiangiogenic activities of genistein in human renal cell carcinoma. Urology, 64, 389-393.
doi:10.1016/j.urology.2004.03.045
|
|
[32]
|
Hillman, G.G., et al. (2001) Genistein potentiates the radiation effect on prostate carcinoma cells. Clinical Cancer Research, 7, 382-390.
|
|
[33]
|
de la Taille, A., et al. (2001) Cancer of the prostate: Influence of nutritional factors. A new nutritional approach. La Presse Médicale, 30, 561-564.
|
|
[34]
|
Ghafar, M.A., et al. (2002) Regression of prostate cancer following administration of genistein combined polysaccharide (GCP), a nutritional supplement: A case report. The Journal of Alternative and Complementary Medicine, 8, 493-497. doi:10.1089/107555302760253694
|
|
[35]
|
Davis, J.N., et al. (2000) Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. International Journal of Oncology, 16, 1091-1097.
|
|
[36]
|
Davis, J.N., Kucuk, O. and Sarkar, F.H. (2002) Expression of prostate-specific antigen is transcriptionally regulated by genistein in prostate cancer cells. Molecular Carcinogenesis, 34, 91-101. doi:10.1002/mc.10053
|
|
[37]
|
Shen, J.C., et al. (2000) Low-dose genistein induces cyclin-dependent kinase inhibitors and G1 cell-cycle arrest in human prostate cancer cells. Molecular Carcinogenesis, 29, 92-102.
doi:10.1002/1098-2744(200010)29:2<92::AID-MC6>3.0.CO;2-Q
|
|
[38]
|
Piao, M., et al. (2006) Inhibition of endothelial cell proliferation, in Vitro angiogenesis, and the down-regulation of cell adhesion-related genes by genistein. Combined with a cDNA microarray analysis. Endothelium, 13, 249266. doi:10.1080/10623320600903940
|
|
[39]
|
Shichinohe, T., et al. (2001) Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Therapy, 8, 879-889. doi:10.1038/sj.cgt.7700388
|
|
[40]
|
Shao, Z.M., et al. (1998) Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Research, 58, 4851-4857.
|
|
[41]
|
Li, Y. and Sarkar, F.H. (2002) Gene expression profiles of genistein-treated PC3 prostate cancer cells. The Journal of Nutrition, 132, 3623-3631.
|
|
[42]
|
Li, Y. and Sarkar, F.H. (2002) Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Letters, 186, 157-164.
doi:10.1016/S0304-3835(02)00349-X
|
|
[43]
|
Sarkar, F.H. and Li, Y. (2002) Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer and Metastasis Reviews, 21, 265-280.
doi:10.1023/A:1021210910821
|
|
[44]
|
Konstantakopoulos, N., et al. (2006) Changes in gene expressions elicited by physiological concentrations of genistein on human endometrial cancer cells. Molecular Carcinogenesis, 45, 752-763. doi:10.1002/mc.20187
|
|
[45]
|
Khoshyomn, S., et al. (2000) Synergistic action of genistein and cisplatin on growth inhibition and cytotoxicity of human medulloblastoma cells. Pediatric Neurosurgery, 33, 123-131. doi:10.1159/000028993
|
|
[46]
|
Raynal, N.J., et al. (2008) Antileukemic activity of genistein, a major isoflavone present in soy products. Journal of Natural Products, 71, 3-7. doi:10.1021/np070230s
|
|
[47]
|
Banerjee, S., et al. (2007) In Vitro and in Vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. International Journal of Cancer, 120, 906-917. doi:10.1002/ijc.22332
|
|
[48]
|
Dijkstra, S.C., et al. (2010) Biomarkers of dietary exposure are associated with lower risk of breast fibroadenomas in Chinese women. The Journal of Nutrition, 140, 1302-1310. doi:10.3945/jn.109.119727
|
|
[49]
|
Vauzour, D., et al. (2007) Inhibition of cellular proliferation by the genistein metabolite 5,7,3',4'-tetrahydroxylisoflavone is mediated by DNA damage and activation of the ATR signalling pathway. Archives of Biochemistry and Biophysics, 468, 159-166.
doi:10.1016/j.abb.2007.09.021
|
|
[50]
|
Meeran, S.M. and Katiyar, S.K. (2008) Cell cycle control as a basis for cancer chemopre-vention through dietary agents. Frontiers in Bioscience, 13, 2191-2202.
doi:10.2741/2834
|
|
[51]
|
Ohigashi, H. and Murakami, A. (2004) Cancer prevention with food factors: Alone and in combination. Biofactors, 22, 49-55. doi:10.1002/biof.5520220109
|
|
[52]
|
Ramos, S. (2007) Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. The Journal of Nutritional Biochemistry, 18, 427-442.
doi:10.1016/j.jnutbio.2006.11.004
|
|
[53]
|
Sarkar, F.H., et al. (2006) The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Reviews in Medicinal Chemistry, 6, 401407.
|
|
[54]
|
Perabo, F.G., et al. (2008) Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer and Prostatic Diseases, 11, 6-12.
doi:10.1038/sj.pcan.4501000
|
|
[55]
|
Nagata, Y., et al. (2007) Dietary isoflavones may protect against prostate cancer in Japanese men. The Journal of Nutrition, 137, 1974-1979.
|
|
[56]
|
Heald, C.L., et al. (2006) Phyto-oestrogen intake in Scottish men: Use of serum to validate a self-administered food-frequency questionnaire in older men. European Journal of Clinical Nutrition, 60, 129-135.
doi:10.1038/sj.ejcn.1602277
|
|
[57]
|
Kurahashi, N., et al. (2007) Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiology, Biomarkers & Prevention, 16, 538-545. doi:10.1158/1055-9965.EPI-06-0517
|
|
[58]
|
Ko, K.P., et al. (2010) Isoflavones from phytoestrogens and gastric cancer risk: A nested case-control study within the Korean Multicenter Cancer Cohort. Cancer Epidemiology, Biomarkers & Preven-tion, 19, 1292-1300.
doi:10.1158/1055-9965.EPI-09-1004
|
|
[59]
|
Cho, J. and Kim, Y. (2002) Sharks: A potential source of antiangiogenic factors and tumor treatments. Marine Biotechnology, 4, 521-525.
doi:10.1007/s10126-002-0064-3
|
|
[60]
|
Williams, J.I., et al. (2001) Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies. Clinical Cancer Research, 7, 724-733.
|
|
[61]
|
Bhargava, P., et al. (2001) A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clinical Cancer Research, 7, 3912-3919.
|
|
[62]
|
Herbst, R.S., et al. (2003) A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clinical Cancer Research, 9, 4108-4115.
|
|
[63]
|
Hao, D., et al. (2003) A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibittor. Clinical Cancer Research, 9, 2465-2471.
|
|
[64]
|
Bayes, M., Rabasseda, X. and Prous, J.R. (2005) Gateways to clinical trials. Methods and Findings in Experimental and Clinical Pharmacology, 27, 331-372.
|
|
[65]
|
Emerson, M.V. and Lauer, A.K. (2007) Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs, 21, 245-257. doi:10.2165/00063030-200721040-00005
|
|
[66]
|
Connolly, B., et al. (2006) Squalamine lactate for exudative age-related macular degeneration. Ophthalmology Clinics of North America, 19, 381-391.
|
|
[67]
|
Michels, S., Schmidt-Erfurth, U. and Rosenfeld, P.J. (2006) Promising new treatments for neovascular age-related macular degeneration. Expert Opinion on Investigational Drugs, 15, 779-793.
doi:10.1517/13543784.15.7.779
|
|
[68]
|
Shepherd, F.A. and Sridhar, S.S. (2003) Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer, 41, 63-72.
doi:10.1016/S0169-5002(03)00144-2
|
|
[69]
|
Li, D., Williams, J.I. and Pietras, R.J. (2002) Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene, 21, 2805-2814.
doi:10.1038/sj.onc.1205410
|
|
[70]
|
Akhter, S., et al. (1999) Squalamine, a novel cationic steroid, specifically inhibits the brush-border Na+/H+ exchanger isoform NHE3. American Journal of Physiology -Cell Physiology, 276, C136-C144.
|
|
[71]
|
Teicher, B.A., et al. (1998) Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Research, 18, 2567-2573.
|
|
[72]
|
Paley, P.J., et al. (1997) Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer, 80, 98-106.
doi:10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A
|
|
[73]
|
Yamamoto, S., et al. (1997) Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. British Journal of Cancer, 76, 1221-1227.
doi:10.1038/bjc.1997.537
|
|
[74]
|
Alvarez, A.A., et al. (1999) The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clinical Cancer Research, 5, 587-591.
|
|
[75]
|
Brunel, J.M., et al. (2005) Squalamine: A polyvalent drug of the future? Current Cancer Drug Targets, 5, 267-272.
|
|
[76]
|
Havre, P.A., et al. (2002) Transformed and tumor-derived human cells exhibit preferential sensitivity to the thiol antioxidants, N-acetyl cysteine and penicillamine. Cancer Research, 62, 1443-1449.
|
|
[77]
|
Alonso, A., et al. (2004) Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: A meta-analysis of randomized, controlled trials. American Journal of Kidney Diseases, 43, 1-9.
|
|
[78]
|
Agarwal, A., et al. (2004) N-acetyl-cysteine promotes angiostatin production and vascular collapse in an orthotopic model of breast cancer. The American Journal of Pathology, 164, 1683-1696.
doi:10.1016/S0002-9440(10)63727-3
|
|
[79]
|
Albini, A., et al. (2001) Inhibition of angiogenesis-driven Kaposi’s sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Research, 61, 8171-8178.
|
|
[80]
|
Choi, C.H., et al. (2007) Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma. Gynecologic Oncology, 104, 64-69.
doi:10.1016/j.ygyno.2006.07.006
|
|
[81]
|
Betten, D.P., et al. (2007) A prospective evaluation of shortened course oral N-acetylcysteine for the treatment of acute acetaminophen poisoning. Annals of Emergency Medicine, 50, 272-279.
doi:10.1016/j.annemergmed.2006.11.010
|
|
[82]
|
Paterson, R.L., Galley, H.F. and Webster, N.R. (2003) The effect of N-acetylcysteine on nuclear factor-kappa B activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression in patients with sepsis. Critical Care Medicine, 31, 2574-2578.
doi:10.1097/01.CCM.0000089945.69588.18
|
|
[83]
|
Uwe, S. (2008) Antiinflammatory interventions of NFkappaB signaling: Potential applications and risks. Biochemical Pharmacology, 75, 1567-1579.
doi:10.1016/j.bcp.2007.10.027
|
|
[84]
|
Vecchiarelli, A., et al. (1994) Macrophage activation by N-acetyl-cysteine in COPD patients. Chest, 105, 806-811.
|
|
[85]
|
Mantovani, G., et al. (2003) Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: Phase II study evaluating clinical, quality of life, and laboratory parameters. Journal of Experimental Therapeutics and Oncology, 3, 205-219.
doi:10.1046/j.1359-4117.2003.01096.x
|
|
[86]
|
Pendyala, L. and Creaven, P.J. (1995) Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial. Cancer Epidemiology, Biomarkers & Prevention, 4, 245251.
|
|
[87]
|
Wolchok, J.D., et al. (2003) Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma Research, 13, 189-196.
doi:10.1097/00008390-200304000-00013
|
|
[88]
|
Haase, M., et al. (2007) Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients. Critical Care Medicine, 35, 1324-1331.
|
|
[89]
|
Mantovani, G., et al. (2002) Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy. Oncology Reports, 9, 887-896.
|
|
[90]
|
Zoran, D.L., et al. (1997) Wheat bran diet reduces tumor incidence in a rat model of colon cancer independent of effects on distal luminal butyrate concentrations. The Journal of Nutrition, 127, 2217-2225.
|
|
[91]
|
Reddy, B.S., et al. (2000) Preventive potential of wheat bran fractions against experimental colon carcinogenesis: Implications for human colon cancer prevention. Cancer Research, 60, 4792-4797.
|
|
[92]
|
Martinez, M.E., et al. (1998) Design and baseline characteristics of study participants in the wheat bran fiber trial. Cancer Epidemiology, Biomarkers & Prevention, 7, 813-816.
|
|
[93]
|
Compher, C.W., et al. (1999) Wheat bran decreases aberrant crypt foci, preserves normal proliferation, and increases intraluminal butyrate levels in experimental colon cancer. Journal of Parenteral Enteral Nutrition, 23, 269277.
|
|
[94]
|
Folino, M., McIntyre, A. and Young, G.P. (1995) Dietary fibers differ in their effects on large bowel epithelial proliferation and fecal fermentation-dependent events in rats. The Journal of Nutrition, 125, 1521-1528.
|
|
[95]
|
Lupton, J.R. and Kurtz, P.P. (1993) Relationship of colonic luminal short-chain fatty acids and pH to in Vivo cell proliferation in rats. The Journal of Nutrition, 123, 15221530.
|
|
[96]
|
Zhang, J. and Lupton, J.R. (1994) Dietary fibers stimulate colonic cell proliferation by different mechanisms at different sites. Nutrition and Cancer, 22, 267-276.
doi:10.1080/01635589409514352
|
|
[97]
|
McIntyre, A., et al. (1991) Different fibers have different regional effects on luminal contents of rat colon. Gastroenterology, 101, 1274-1281.
|
|
[98]
|
McIntyre, A., Gibson, P.R. and Young, G.P. (1993) Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut, 34, 386391. doi:10.1136/gut.34.3.386
|
|
[99]
|
Newmark, H.L. and Lupton, J.R. (1990) Determinants and consequences of colonic luminal pH: Implications for colon cancer. Nutrition and Cancer, 14, 161-173.
doi:10.1080/01635589009514091
|
|
[100]
|
Kestell, P., et al. (1999) Studies on the mechanism of cancer protection by wheat bran: Effects on the absorption, metabolism and excretion of the food carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline (IQ). Carcinogenesis, 20, 2253-2260. doi:10.1093/carcin/20.12.2253
|
|
[101]
|
Ghoneum, M. and Matsuura, M. (2004) Augmentation of macrophage phagocytosis by modified arabinoxylan rice bran (MGN-3/biobran). International Journal of Immunopathology and Pharmacology, 17, 283-292.
|
|
[102]
|
Chang, H., et al. (2004) Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leukemia Research, 28, 43-48.
doi:10.1016/S0145-2126(03)00180-2
|
|
[103]
|
Lee, C.Y. and Wan, J.M. (2002) Immunoregulatory and antioxidant performance of alpha-tocopherol and selenium on human lymphocytes. Biological Trace Element Research, 86, 123-136. doi:10.1385/BTER:86:2:123
|
|
[104]
|
Muralikrishna, G. and Rao, M.V. (2007) Cereal noncellulosic polysaccharides: Structure and function relationship—An overview. Critical Reviews in Food Science and Nutrition, 47, 599-610.
doi:10.1080/10408390600919056
|
|
[105]
|
Glei, M., et al. (2006) Both wheat (Triticum aestivum) bran arabinoxylans and gut flora-mediated fermentation products protect human colon cells from genotoxic activities of 4-hydroxynonenal and hydrogen peroxide. Journal of Agricultural and Food Chemistry, 54, 20882095. doi:10.1021/jf052768e
|
|
[106]
|
Ferreira, I.C., et al. (2010) Compounds from wild mushrooms with antitumor potential. Anti-Cancer Agents in Medicinal Chemistry, 10, 424-436.
|
|
[107]
|
Wasser, S.P. and Weis, A.L. (1999) Therapeutic effects of substances occurring in higher basidiomycetes mushrooms: A modern perspective. Critical Reviews in Immunology, 19, 65-96.
|
|
[108]
|
Chihara, G. (1992) Recent progress in immunopharmacology and therapeutic effects of polysaccha-rides. Developments in Biological Standardization, 77, 191-197.
|
|
[109]
|
Ooi, V.E. and Liu, F. (2000) Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Current Medicinal Chemistry, 7, 715-729.
|
|
[110]
|
Borchers, A.T., et al. (1999) Mushrooms, tumors, and immunity. Proceedings of the Society for Experimental Biology and Medicine, 221, 281-293.
doi:10.1046/j.1525-1373.1999.d01-86.x
|
|
[111]
|
Jong, S.C., Birmingham, J.M. and Pai, S.H. (1991) Immunomodulatory substances of fungal origin. Journal of Immunology and Immunopharmacology, 9, 115-122.
|
|
[112]
|
Hobbs, C.R. (2000) Medicinal value of Lentinus edodes (Berk.) Sing. (Agaricomy-cetideae). A literature review. International Journal of Medicinal Mushrooms, 2, 287302.
|
|
[113]
|
Taguchi, T., et al. (1985) Results of phase III study of lentinan. Gan to Kagaku Ryoho, 12, 366-378.
|
|
[114]
|
Oba, K., et al. (2009) Individual patient based metaanalysis of lentinan for unresectable/recurrent gastric cancer. Anticancer Research, 29, 2739-2745.
|
|
[115]
|
Hazama, S., et al. (2009) Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer. Anticancer Research, 29, 2611-2617.
|
|
[116]
|
Ross, G.D., et al. (1999) Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology, 42, 61-74. doi:10.1016/S0162-3109(99)00013-2
|
|
[117]
|
Kerekgyarto, C., et al. (1996) Strain differences in the cytotoxic activity and TNF production of murine macrophages stimulated by lentinan. International Journal of Immunopharmacology, 18, 347-353.
doi:10.1016/S0192-0561(96)00038-0
|
|
[118]
|
Yoshino, S., et al. (2010) Improvement of QOL and prognosis by treatment of superfine dispersed lentinan in patients with advanced gastric cancer. Hepatogastroenterology, 57, 172-177.
|
|
[119]
|
Kataoka, H., et al. (2009) Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life. Hepatogastroenterology, 56, 547-550.
|
|
[120]
|
Wang, J.L., et al. (2012) Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma. Molecular Medicine Report, 5, 745-748.
|
|
[121]
|
Vanotti, A., et al. (2007) Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies. CNS Drugs, 21, 3-12.
doi:10.2165/00023210-200721001-00002
|
|
[122]
|
D. De Grandis, (2007) Acetyl-l-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: A short review. CNS Drugs, 21, 39-43.
doi:10.2165/00023210-200721001-00006
|
|
[123]
|
Youle, M. (2007) Acetyl-l-carnitine in HIV-associated antiretroviral toxic neuropathy. CNS Drugs, 21, 25-30.
doi:10.2165/00023210-200721001-00004
|
|
[124]
|
Sima, A.A. (2007) Acetyl-l-carnitine in diabetic polyneuropathy: Experimental and clinical data. CNS Drugs, 21, 13-23. doi:10.2165/00023210-200721001-00003
|
|
[125]
|
Youle, M. and Osio, M. (2007) A double-blind, parallel-group, placebo-controlled, multicentre study of acetyll-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Medicine, 8, 241-250.
doi:10.1111/j.1468-1293.2007.00467.x
|
|
[126]
|
Murosaki, S., et al. (2007) A combination of caffeine, arginine, soy isoflavones, and L-carnitine enhances both lipolysis and fatty acid oxidation in 3T3-L1 and HepG2 cells in Vitro and in KK mice in Vivo. The Journal of Nutrition, 137, 2252-2257.
|
|
[127]
|
Carroll, J.K., et al. (2007) Pharmacologic treatment of cancer-related fatigue. The Oncologist, 12, 43-51.
doi:10.1634/theoncologist.12-S1-43
|
|
[128]
|
Gramignano, G., et al. (2006) Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition, 22, 136-145.
doi:10.1016/j.nut.2005.06.003
|
|
[129]
|
Cruciani, R.A., et al. (2006) Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: A phase I/II study. Journal of Pain and Symptom Management, 32, 551-559.
doi:10.1016/j.jpainsymman.2006.09.001
|
|
[130]
|
Sood, A., et al. (2007) A critical review of complementtary therapies for cancer-related fatigue. Integrative Cancer Therapies, 6, 8-13. doi:10.1177/1534735406298143
|
|
[131]
|
Delaney, C.E., Hopkins, S.P. and Addison, C.L. (2007) Supplementation with l-carnitine does not reduce the efficacy of epirubicin treatment in breast cancer cells. Cancer Letters, 252, 195-207.
doi:10.1016/j.canlet.2006.12.027
|
|
[132]
|
Dong, M.H. and Kaunitz, J.D. (2006) Gastroduodenal mucosal defense. Current Opinion in Gastroenterology, 22, 599-606. doi:10.1097/01.mog.0000245540.87784.75
|
|
[133]
|
Lebrun, C., et al. (2006) Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Multiple Sclerosis Journals, 12, 321-324. doi:10.1191/135248506ms1275oa
|
|
[134]
|
Mantovani, G., et al. (2003) Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: Assessment of the most important laboratory indexes of cachexia and oxidative stress. Journal of Molecular Medicine, 81, 664-673.
doi:10.1007/s00109-003-0476-1
|
|
[135]
|
Weitsman, G.E., et al. (2003) Vitamin D enhances caspase-dependent and independent TNF-induced breast cancer cell death: The role of reactive oxygen species. Annals of New York Academy of Sciences, 1010, 437-440.
|
|
[136]
|
Mantovani, G., et al. (2003) The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: Correlation with disease progression. Free Radical Research, 37, 213-223. doi:10.1080/10715760303849
|
|
[137]
|
Zahid, M., et al. (2007) Inhibition of depurinating estrogen-DNA adduct formation by natural compounds. Chemical Research in Toxicology, 20, 1947-1953.
doi:10.1021/tx700269s
|
|
[138]
|
Novotny, L., Rauko, P. and Cojocel, C. (2008) Alphalipoic acid: The potential for use in cancer therapy. Neoplasma, 55, 81-86.
|
|
[139]
|
Rock, E. and DeMichele, A. (2003) Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. The Journal of Nutrition, 133, 3785S-3793S.
|
|
[140]
|
Schwartz, L., et al. (2012) Tumor regression with a combination of drugs interfering with the tumor metabolism: Efficacy of hydroxycitrate, lipoic acid and capsaicin. Investigational New Drugs, 31, 256-264.
|
|
[141]
|
Moungjaroen, J., et al. (2006) Reactive oxygen species mediate caspase activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down-regulation. The Journal of Pharmacology and Experimental Therapeutics, 319, 1062-1069.
doi:10.1124/jpet.106.110965
|
|
[142]
|
Miquel, J., et al. (2006) Menopause: A review on the role of oxygen stress and favorable effects of dietary antioxidants. Archives of Gerontology and Geriatrics, 42, 289306. doi:10.1016/j.archger.2005.08.005
|
|
[143]
|
Valko, M., et al. (2006) Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chemico-Biological Interactions, 160, 1-40.
doi:10.1016/j.cbi.2005.12.009
|
|
[144]
|
Ratnam, D.V., et al. (2006) Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. Journal of Controlled Release, 113, 189-207.
doi:10.1016/j.jconrel.2006.04.015
|
|
[145]
|
Matkovics, A. (2006) Recent changes in concepts of antioxidant treatment. Orvosi Hetilap, 147, 747-752.
|
|
[146]
|
Schmelzer, C., et al. (2007) Functional connections and pathways of coenzyme Q10-inducible genes: An in-silico study. IUBMB Life, 59, 628-633.
doi:10.1080/15216540701545991
|
|
[147]
|
Pepe, S., et al. (2007) Coenzyme Q10 in cardiovascular disease. Mitochondrion, 7, S154-S167.
doi:10.1016/j.mito.2007.02.005
|
|
[148]
|
Rosenfeldt, F., et al. (2005) Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in Vitro contractility of myocardial tissue. The Journal of Thoracic and Cardiovascular Surgery, 129, 25-32.
doi:10.1016/j.jtcvs.2004.03.034
|
|
[149]
|
Bailey, D.M., et al. (2007) Electron paramagnetic spectroscopic evidence of exercise-induced free radical accumulation in human skeletal muscle. Free Radical Research, 41, 182-190. doi:10.1080/10715760601028867
|
|
[150]
|
Thomas, J.E., Lee, N. and Thompson, P.D. (2007) Statins provoking MELAS syndrome. A case report. European Neurology, 57, 232-235. doi:10.1159/000101287
|
|
[151]
|
Langsjoen, P.H., et al. (2005) Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. Biofactors, 25, 147-152.
doi:10.1002/biof.5520250116
|
|
[152]
|
Lamperti, C., et al. (2005) Muscle coenzyme Q10 level in statin-related myopathy. Archives of Neurology, 62, 17091712. doi:10.1001/archneur.62.11.1709
|
|
[153]
|
Stocker, R., et al. (2006) Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: A prospective case-control study from the LIPID study. Atherosclerosis, 187, 198-204.
doi:10.1016/j.atherosclerosis.2005.09.004
|
|
[154]
|
Siemieniuk, E. and Skrzydlewska, E. (2005) Coenzyme Q10: Its biosynthesis and biological significance in animal organisms and in humans. Postepy Higieny I Medycyny Doswiadczalnej (Online), 59, 150-159.
|
|
[155]
|
Tavintharan, S., et al. (2007) Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with highdose simvastatin: A possible role in statin-induced hepatotoxicity? Toxicology and Applied Pharmacology, 223, 173-179. doi:10.1016/j.taap.2007.05.013
|
|
[156]
|
McCarthy, S., et al. (2004) Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble Coenzyme Q10. Toxicology and Applied Pharmacology, 201, 21-31. doi:10.1016/j.taap.2004.04.019
|
|
[157]
|
Korkina, L., et al. (2003) Coenzyme Q10-containing composition (Immugen) protects against occupational and environmental stress in workers of the gas and oil Industry. Biofactors, 18, 245-254. doi:10.1002/biof.5520180227
|
|
[158]
|
Bruge, F., et al. (2003) Effect of UV-C mediated oxidative stress in leukemia cell lines and its relation to ubiquinone content. Biofactors, 18, 51-63.
doi:10.1002/biof.5520180207
|
|
[159]
|
Ebadi, M., et al. (2004) Coenzyme Q10 inhibits mitochondrial complex-1 down-regulation and nuclear factor-kappa B activation. Journal of Cellular and Molecular Medicine, 8, 213-222.
doi:10.1111/j.1582-4934.2004.tb00276.x
|
|
[160]
|
Hyun, D.H., et al. (2006) Calorie restriction up-regulates the plasma membrane redox system in brain cells and suppresses oxidative stress during aging. Proceedings of the National Academy of Sciences of the United States of America, 103, 19908-19912.
doi:10.1073/pnas.0608008103
|
|
[161]
|
Bhagavan, H.N., et al. (2007) Assessment of coenzyme Q10 absorption using an in Vitro digestion-Caco-2 cell model. International Journal of Pharmaceutics, 333, 112-117. doi:10.1016/j.ijpharm.2006.10.007
|
|
[162]
|
Niklowitz, P., et al. (2007) Coenzyme Q10 concentration in the plasma of children suffering from acute lymphoastic leukaemia before and during induction treatment. Biofactors, 29, 83-89. doi:10.1002/biof.552029208
|
|
[163]
|
van Dalen, E.C., Caron, H.N. and Kremer, L.C. (2007) Prevention of anthracycline-induced cardiotoxicity in children: The evidence. European Journal of Cancer, 43, 1134-1140. doi:10.1016/j.ejca.2007.01.040
|
|
[164]
|
Conklin, K.A. (2005) Coenzyme Q10 for prevention of anthracycline-induced cardiotoxicity. Integrative Cancer Therapies, 4, 110-130. doi:10.1177/1534735405276191
|
|
[165]
|
Bryant, J., et al. (2007) Cardioprotection against the toxic effects of anthracyclines given to children with cancer: A systematic review. Health Technology Assessment, 11, iii, ix-x, 1-84.
|
|
[166]
|
Premkumar, V.G., et al. (2007) Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy. Biological & Pharmaceutical Bulletin, 30, 367-370.
doi:10.1248/bpb.30.367
|
|
[167]
|
Yuvaraj, S., et al. (2007) Ameliorating effect of coenzyme Q10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins. Clinical Biochemistry, 40, 623628. doi:10.1016/j.clinbiochem.2007.02.003
|
|
[168]
|
Palan, P.R., et al. (2005) Effects of menopause and hormone replacement therapy on serum levels of coenzyme Q10 and other lipid-soluble antioxidants. Biofactors, 25, 61-66. doi:10.1002/biof.5520250107
|
|
[169]
|
Rusciani, L., et al. (2007) Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: A 3-year trial with recombinant interferon-alpha and 5-year follow-up. Melanoma Research, 17, 177-183.
doi:10.1097/CMR.0b013e32818867a0
|
|
[170]
|
Rusciani, L., et al. (2006) Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression. Journal of the American Academy of Dermatology, 54, 234-241. doi:10.1016/j.jaad.2005.08.031
|
|
[171]
|
Brea-Calvo, G., et al. (2006) Chemotherapy induces an increase in coenzyme Q10 levels in cancer cell lines. Free Radical Biology and Medicine, 40, 1293-1302.
doi:10.1016/j.freeradbiomed.2005.11.014
|
|
[172]
|
Roffe, L., Schmidt, K. and Ernst, E. (2004) Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: A systematic review. Journal of Clinical Oncology, 22, 4418-4424.
|
|
[173]
|
Fulda, S. and Debatin, K.M. (2006) Resveratrol modulation of signal transduction in apoptosis and cell survival: A mini-review. Cancer Detection and Prevention, 30, 217-223. doi:10.1016/j.cdp.2006.03.007
|
|
[174]
|
Vinod, B.S., Maliekal, T.T. and Anto, R.J. (2012) Phytochemicals as chemosensitizers: From molecular mechanism to clinical significance. Antioxidants & Redox Signaling, 18, 1307-1348.
|
|
[175]
|
Hull, M.A. (2012) Nutritional agents with anti-lnflammatory properties in chemoprevention of colorectal neoplasia. Recent Results in Cancer Research, 191, 143-156.
doi:10.1007/978-3-642-30331-9_8
|
|
[176]
|
Athar, M., et al. (2007) Resveratrol: A review of preclinical studies for human cancer prevention. Toxicology and Applied Pharmacology, 224, 274-283.
doi:10.1016/j.taap.2006.12.025
|
|
[177]
|
Leon-Galicia, I., et al. (2012) Resveratrol induces downregulation of DNA repair genes in MCF-7 human breast cancer cells. European Journal Cancer Prevention, 22, 11-20.
|
|
[178]
|
Kim, Y.S., Sull, J.W. and Sung, H.J. (2012) Suppressing effect of resveratrol on the migration and invasion of human metastatic lung and cervical cancer cells. Molecular Biology Reports, 39, 8709-8716.
doi:10.1007/s11033-012-1728-3
|
|
[179]
|
Scoditti, E., et al. (2012) Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: A potentially protective mechanism in atherosclerotic vascular disease and cancer. Archives of Biochemistry and Biophysics, 527, 81-89.doi:10.1016/j.abb.2012.05.003
|
|
[180]
|
Liu, M.M., Huang, Y. and Wang, J. (2012) Developing phytoestrogens for breast cancer prevention. Anti-Cancer Agents in Medicinal Chemistry, 12, 1306-1313.
|
|
[181]
|
Shankar, S., Singh, G. and Srivastava, R.K. (2007) Chemoprevention by resveratrol: Molecular mechanisms and therapeutic potential. Frontiers in Bioscience, 12, 48394854. doi:10.2741/2432
|
|
[182]
|
Boocock, D.J., et al. (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiology, Biomarkers & Prevention, 16, 1246-1252.
doi:10.1158/1055-9965.EPI-07-0022
|
|
[183]
|
Delmas, D., et al. (2006) Resveratrol as a chemopreventive agent: A promising molecule for fighting cancer. Current Drug Targets, 7, 423-442.
|
|
[184]
|
Aziz, M.H., et al. (2005) Chemoprevention of skin cancer by grape constituent resveratrol: Relevance to human disease? FASEB Journal, 19, 1193-1195.
|
|
[185]
|
Stojanovic, S., Sprinz, H. and Brede, O. (2001) Efficiency and mechanism of the antioxidant action of trans-resveratrol and its analogues in the radical liposome oxidation. Archives of Biochemistry and Biophysics, 391, 79-89. doi:10.1006/abbi.2001.2388
|
|
[186]
|
Brito, P., Almeida, L.M. and Dinis, T.C. (2002) The interaction of resveratrol with ferrylmyoglobin and peroxynitrite; Protection against LDL oxidation. Free Radical Research, 36, 621-631.
doi:10.1080/10715760290029083
|
|
[187]
|
Bradamante, S., Barenghi, L. and Villa, A. (2004) Cardiovascular protective effects of resveratrol. Cardiovascular Drug Reviews, 22, 169-188.
doi:10.1111/j.1527-3466.2004.tb00139.x
|
|
[188]
|
Das, S. and Das, D.K. (2007) Anti-inflammatory responses of resveratrol. Inflammation & Allergy Drug Targets, 6, 168-173. doi:10.2174/187152807781696464
|
|
[189]
|
Goswami, S.K. and Das, D.K. (2009) Resveratrol and chemoprevention. Cancer Letters, 284, 1-6.
doi:10.1016/j.canlet.2009.01.041
|
|
[190]
|
Aggarwal, B.B., et al. (2004) Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Research, 24, 2783-2840.
|
|
[191]
|
Gescher, A.J. and Steward, W.P. (2003) Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: A conundrum. Cancer Epidemiology, Biomarkers & Prevention, 12, 953957.
|
|
[192]
|
Bass, T.M., et al. (2007) Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mechanisms of Ageing and Development, 128, 546-552.
doi:10.1016/j.mad.2007.07.007
|
|
[193]
|
Bartel, J., et al. (2007) Activity of the glutathione peroxidase-2. Differences in the selenium-dependent expression between colon and small intestine. Cancer Genomics & Proteomics, 4, 369-372.
|
|
[194]
|
Steinbrenner, H., et al. (2007) Post-translational processing of selenoprotein P: Implications of glycosylation for its utilisation by target cells. Biological Chemistry, 388, 1043-1051. doi:10.1515/BC.2007.136
|
|
[195]
|
Philchenkov, A., et al. (2007) Comparative analysis of apoptosis induction by selenium compounds in human lymphoblastic leukemia MT-4 cells. Experimental Oncology, 29, 257-261.
|
|
[196]
|
Meplan, C. and Hesketh, J. (2012) The influence of selenium and selenoprotein gene variants on colorectal cancer risk. Mutagenesis, 27, 177-186.
doi:10.1093/mutage/ger058
|
|
[197]
|
Bardia, A., et al. (2008) Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: Systematic review and meta-analysis. Mayo Clinic Proceedings, 83, 23-34.
doi:10.4065/83.1.23
|
|
[198]
|
Li, S., et al. (2007) Doxorubicin and selenium cooperatively induce fas signaling in the absence of Fas/Fas ligand interaction. Anticancer Research, 27, 3075-3082.
|
|
[199]
|
Santos, R.A. and Takahashi, C.S. (2008) Anticlastogenic and antigenotoxic effects of selenomethionine on doxorubicin-induced damage in Vitro in human lymphocytes. Food and Chemical Toxicology, 46, 671-677.
doi:10.1016/j.fct.2007.09.090
|
|
[200]
|
Cheung, E., et al. (2008) Diet and prostate cancer risk reduction. Expert Review of Anticancer Therapy, 8, 43-50.
doi:10.1586/14737140.8.1.43
|
|
[201]
|
Juliger, S., et al. (2007) Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-kappaB inhibition and the rapid generation of other selenium species. Cancer Research, 67, 10984-10992.
doi:10.1158/0008-5472.CAN-07-0519
|
|
[202]
|
Murawaki, Y., et al. (2008) Aberrant expression of selenoproteins in the progression of colorectal cancer. Cancer Letters, 259, 218-230.
doi:10.1016/j.canlet.2007.10.019
|
|
[203]
|
Ma, J.L., et al. (2012) Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institiute, 104, 488-492. doi:10.1093/jnci/djs003
|
|
[204]
|
Chen, K.M., et al. (2007) Inhibition of nuclear factorkappaB DNA binding by organoselenocyanates through covalent modification of the p50 subunit. Cancer Research, 67, 10475-10483.
doi:10.1158/0008-5472.CAN-07-2510
|
|
[205]
|
Lee, E.H., et al. (2011) Effects of selenium supplements on cancer prevention: Meta-analysis of randomized controlled trials. Nutrition and Cancer, 63, 1185-1195.
doi:10.1080/01635581.2011.607544
|
|
[206]
|
Sanmartin, C., et al. (2011) Selenium and clinical trials: New therapeutic evidence for multiple diseases. Current Medicinal Chemistry, 18, 4635-4650.
|
|
[207]
|
Cuello, S., et al. (2007) Selenium methylselenocysteine protects human hepatoma HepG2 cells against oxidative stress induced by tert-butyl hydroperoxide. Analytical and Bioanalytical Chemistry, 389, 2167-2178.
doi:10.1007/s00216-007-1626-z
|
|
[208]
|
Schmutzler, C., et al. (2007) Selenoproteins of the thyroid gland: Expression, localization and possible function of glutathione peroxidase 3. Biological Chemistry, 388, 1053-1059. doi:10.1515/BC.2007.122
|
|
[209]
|
Yanagisawa, H. (2008) Zinc deficiency and clinical practice—Validity of zinc preparations. Yakugaku Zasshi, 128, 333-339. doi:10.1248/yakushi.128.333
|
|
[210]
|
Yan, M., et al. (2008) Zinc deficiency alters DNA damage response genes in normal human prostate epithelial cells. The Journal of Nutrition, 138, 667-673.
|
|
[211]
|
Lonn, E.M. and Yusuf, S. (1997) Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data. The Canadian Journal of Cardiology, 13, 957-965.
|
|
[212]
|
Bansal, S.S., et al. (2011) Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prevention Research, 4, 1158-1171.
doi:10.1158/1940-6207.CAPR-10-0006
|
|
[213]
|
Kaefer, C.M. and Milner, J.A. (2011) Herbs and spices in cancer prevention and treatment, in herbal medicine, In: I.F.F. Benzie and S. Wachtel-Galor, Eds., Biomolecular and Clinical Aspects, Llc, Boca Raton.
|
|
[214]
|
Gullett, N.P., et al. (2010) Cancer prevention with natural compounds. Seminars in Oncology, 37, 258-281.
doi:10.1053/j.seminoncol.2010.06.014
|
|
[215]
|
Taylor, C.K., et al. (2009) The effect of genistein aglycone on cancer and cancer risk: A review of in Vitro, preclinical, and clinical studies. Nutrition Reviews, 67, 398415. doi:10.1111/j.1753-4887.2009.00213.x
|
|
[216]
|
Gerhauser, C. (2013) Cancer chemoprevention and nutriepigenetics: State of the art and future challenges. Topics in Current Chemistry, 329, 73-132.
doi:10.1007/128_2012_360
|
|
[217]
|
Li, Y., et al. (2011) Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. The Journal of Nutritional Biochemistry, 22, 799-806. doi:10.1016/j.jnutbio.2010.11.001
|
|
[218]
|
Kim, Y.S., et al. (2012) Cancer stem cells: Potential target for bioactive food components. The Journal of Nutritional Biochemistry, 23, 691-698.
doi:10.1016/j.jnutbio.2012.03.002
|
|
[219]
|
Ullah, M.F., et al. (2012) Ascorbic acid in cancer chemoprevention: Translational perspectives and efficacy. Current Drug Targets, 13, 1757-1771.
doi:10.2174/138945012804545669
|
|
[220]
|
Khan, S.I., et al. (2012) Epigenetic events associated with breast cancer and their prevention by dietary components targeting the epigenome. Chemical Research in Toxicology, 25, 61-73. doi:10.1021/tx200378c
|
|
[221]
|
Ozten-Kandas, N. and Bosland, M.C. (2011) Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants-In Vivo evidence. Journal of Carcinogenesis, 10, 27. doi:10.4103/1477-3163.90438
|
|
[222]
|
Khan, N., Adhami, V.M. and Mukhtar, H. (2010) Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocrine-Related Cancer, 17, R39-R52.
doi:10.1677/ERC-09-0262
|
|
[223]
|
Howells, L.M., et al. (2011) Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases—Safety, pharmacokinetics, and pharmacodynamics. Cancer Prevention Research, 4, 1419-1425.
doi:10.1158/1940-6207.CAPR-11-0148
|
|
[224]
|
Ye, F., et al. (2012) Suppression of esophageal cancer cell growth using curcumin, (-)-epigallocatechin-3-gallate and lovastatin. World Journal of Gastroenterology, 18, 126135. doi:10.3748/wjg.v18.i2.126
|
|
[225]
|
Hossain, D.M., et al. (2012) Curcumin: The multi-targeted therapy for cancer regression. Front in Bioscience, 4, 335-355.
|
|
[226]
|
Basnet, P. and Skalko-Basnet, N. (2011) Curcumin: An anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules, 16, 4567-4598.
doi:10.3390/molecules16064567
|
|
[227]
|
Darvesh, A.S., Aggarwal, B.B. and Bishayee, A. (2012) Curcumin and liver cancer: A review. Current Pharmaceutical Biotechnology, 13, 218-228.
|
|
[228]
|
Shureiqi, I. and Baron, J.A. (2011) Curcumin chemoprevention: The long road to clinical translation. Cancer Prevention Research, 4, 296-298.
doi:10.1158/1940-6207.CAPR-11-0060
|
|
[229]
|
Rahman, M.A., Amin, A.R. and Shin, D.M. (2010) Chemopreventive potential of natural compounds in head and neck cancer. Nutrition and Cancer, 62, 973-987.
doi:10.1080/01635581.2010.509538
|
|
[230]
|
Shehzad, A., Wahid, F. and Lee, Y.S. (2010) Curcumin in cancer chemoprevention: Molecular targets, pharmacokinetics, bioavailability, and clinical trials. Archiv der Pharmazie, 343, 489-499.
doi:10.1002/ardp.200900319
|
|
[231]
|
Juan, M.E., Alfaras, I. and Planas, J.M. (2012) Colorectal cancer chemoprevention by trans-resveratrol. Pharmacological Research, 65, 584-591.
doi:10.1016/j.phrs.2012.03.010
|
|
[232]
|
Scott, E., et al. (2012) Resveratrol in human cancer chemoprevention—Choosing the “right” dose. Molecular Nutrition & Food Research, 56, 7-13.
doi:10.1002/mnfr.201100400
|
|
[233]
|
Vang, O., et al. (2011) What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One, 6, e19881.
doi:10.1371/journal.pone.0019881
|